Fig. 4From: Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathwaysBiomarkers and their mutation in BC. Relationship between PIK3CA (A), HRAS (B), and survival rate and prognosis of BC patients. C Relationship between PIK3CA and stages of BC. D Relationship between HRAS and stages of BC. E Their mutation rates in four major studies. F Their specific mutation rates in 18 studies. G Mutation sites of PIK3CA. H Mutation sites of HRASBack to article page